SYNBIOTIC SE · ISIN: DE000A3E5A59 · EQS - Company News

WEECO Pharma boosts SYNBIOTIC's sales

The acquisition of WEECO Pharma by the European hemp and cannabis group SYNBIOTIC SE (ISIN DE000A3E5A59 | WKN A3E5A5) is proving to be a valuable deal in the truest sense of the word. WEECO Pharma is well above the previously planned revenue target for 2024, at EUR 6.75 million as of the end of October 2024. Revenues of over EUR 8 million are expected for the full year 2024. For this reason, WEECO Pharma's sales plans for 2025 and 2026 will be realistically, but still conservatively, adjusted up...

XETR:SBX Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News SYNBIOTIC SE

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (3)
Directors Dealings (356)
Short Selling (DE) (0)
Short Selling (UK) (0)
14 November 2024 01:30PM
WEECO Pharma boosts SYNBIOTIC's sales
DE000A3E5A59
The acquisition of WEECO Pharma by the European hemp and cannabis group SYNBIOTIC SE (ISIN DE000A3E5A59 | WKN A3E5A5) is proving to be a valuable deal in the truest sense of the word. WEECO Pharma is well above the previously planned revenue target for 2024, at EUR 6.75 million as of the end of October 2024. Revenues of over EUR 8 million are expec...
SYNBIOTIC SE
About the publication
27 September 2024 11:19AM
Annual General Meeting supports SYNBIOTIC's growth plans with over 99 percent approval
DE000A3E5A59
The Annual General Meeting of SYNBIOTIC SE (ISIN DE000A3E5A59 | WKN A3E5A5) has confirmed the strategic growth course of the European industrial hemp and cannabis company group with an overwhelming majority. At the virtual Annual General Meeting on Friday, 20 September 2024, the shareholders unreservedly approved the plans for the current and comin...
SYNBIOTIC SE
About the publication
16 August 2024 12:30PM
Increasing sales drive growth
DE000A3E5A59
The Annual General Meeting of SYNBIOTIC SE (ISIN DE000A3E5A59 | WKN A3E5A5), one of Europe's leading industrial hemp and cannabis companies, will take place on Friday, 20 September 2024. In the run-up to the Annual General Meeting, Daniel Kruse, CEO of SYNBIOTIC, gave an initial outlook on current developments and figures: "WEECO Pharma has achieve...
SYNBIOTIC SE
About the publication
23 May 2024 10:31AM
SYNBIOTIC and CEO Daniel Kruse on roadshow
DE000A3E5A59
The leading European industrial hemp and cannabis group SYNBIOTIC is increasing its public presence. "We want to be even more visible and approachable in the professional world and for our investors," explains Daniel Kruse, CEO of SYNBIOTIC. "The aim is to position the enormous potential of hemp in the centre of society. It's time to end the demoni...
SYNBIOTIC SE
About the publication
23 May 2024 10:31AM
SYNBIOTIC and CEO Daniel Kruse on roadshow
DE000A3E5A59
The leading European industrial hemp and cannabis group SYNBIOTIC is increasing its public presence. "We want to be even more visible and approachable in the professional world and for our investors," explains Daniel Kruse, CEO of SYNBIOTIC. "The aim is to position the enormous potential of hemp in the centre of society. It's time to end the demoni...
SYNBIOTIC SE
About the publication
08 May 2024 02:27PM
SYNBIOTIC significantly expands its position in the medical cannabis market
DE000A3E5A59
The German industrial hemp and cannabis group SYNBIOTIC SE acquires WEECO Pharma GmbH from Hildesheim/Germany. The merger makes SYNBIOTIC one of the most important players on the German and European market for medicinal cannabis. "With WEECO Pharma, our group of companies now has a full range of high-quality cannabis flowers. Together with our othe...
SYNBIOTIC SE
About the publication
25 April 2024 12:33PM
Federal Ministry for Economic Affairs and Climate Protection funds bio-economy project
DE000A3E5A59
The Federal Ministry for Economic Affairs and Climate Protection (BMWK) is funding a Hanf Farm project in the field of industrial bio-economy with 1.6 million euros. The official funding decision has now been handed over to Managing Director Rafael Dulon and Project Manager Michael Bieder by State Secretary Stefan Wenzel at the Hanover Trade Fair. ...
SYNBIOTIC SE
About the publication
23 April 2024 10:33AM
Enormous competitive advantages through cannabinoid extracts and isolates from own production
DE000A3E5A59
The German industrial hemp and cannabis group SYNBIOTIC SE acquires Ilesol Pharmaceuticals from Varaždin/Croatia. Ilesol has a 3,400 m2 production facility for the manufacture of cannabinoid extracts and isolates. The company also produces and distributes its own CBD natural cosmetics range. With the acquisition of Ilesol, SYNBIOTIC will be able to...
SynBiotic SE
About the publication
21 August 2023 06:31AM
The Munich-based company acquires majority stake in CannaCare Health and appoints Daniel Kruse as CEO
DE000A3E5A59
Multi-entrepreneur Frank Otto invests in SynBiotic SE: The Munich-based company acquires majority stake in CannaCare Health and appoints Daniel Kruse as CEO Multi-entrepreneur Frank Otto invests 3 million euros in SynBiotic SE SynBiotic acquires majority stake in CBD retail expert Canna Care Health GmbH with its CBD network marketing subsidiary W...
SynBiotic SE
About the publication
24 November 2022 10:13AM
SynBiotic SE attracts Canopy Growth founder Bruce Linton as Chairman of newly created Advisory Board
DE000A3E5A59
SynBiotic SE attracts Canopy Growth founder Bruce Linton as Chairman of newly created Advisory Board   Munich, 24th November 2022:   SynBiotic SE, (SBX.DE) one of Germany’s leading cannabinoid companies, accelerates implementation of the operational platform to achieve market leadership in the upcoming national legalization of recreational cann...
SynBiotic SE
About the publication
24 November 2022 10:13AM
SynBiotic SE attracts Canopy Growth founder Bruce Linton as Chairman of newly created Advisory Board
DE000A3E5A59
SynBiotic SE attracts Canopy Growth founder Bruce Linton as Chairman of newly created Advisory Board   Munich, 24th November 2022:   SynBiotic SE, (SBX.DE) one of Germany’s leading cannabinoid companies, accelerates implementation of the operational platform to achieve market leadership in the upcoming national legalization of recreational cann...
SynBiotic SE
About the publication
31 October 2022 11:05AM
SynBiotic SE completes successfully capital increase and places all new shares
DE000A3E5A59
SynBiotic SE completes successfully capital increase and places all new shares   Munich, October 31, 2022   SynBiotic SE, as Europe's largest listed group of companies in the hemp and cannabis sector, has successfully completed the cash capital increase resolved on October 28, 2022. All 191,739 new shares were placed at the subscription price o...
SynBiotic SE
About the publication
31 October 2022 11:05AM
SynBiotic SE completes successfully capital increase and places all new shares
DE000A3E5A59
SynBiotic SE completes successfully capital increase and places all new shares   Munich, October 31, 2022   SynBiotic SE, as Europe's largest listed group of companies in the hemp and cannabis sector, has successfully completed the cash capital increase resolved on October 28, 2022. All 191,739 new shares were placed at the subscription price o...
SynBiotic SE
About the publication
26 October 2022 01:58PM
“Like winning the lottery” - SynBiotic SE comments on key points paper (“Eckpunktepapier”)
DE000A3E5A59
    “Like winning the lottery” SynBiotic SE comments on key points paper (“Eckpunktepapier”)     October 26, 2022: At today's federal press conference on the upcoming cannabis legalization, the final draft of the key points paper (“Eckpunktepapier”) of the federal government was presented. Among other points, concrete plans relating to the cu...
SynBiotic SE
About the publication
26 October 2022 01:58PM
SynBiotic SE: “Like winning the lottery” - SynBiotic SE comments on key points paper (“Eckpunktepapier”)
DE000A3E5A59
    “Like winning the lottery” SynBiotic SE comments on key points paper (“Eckpunktepapier”)     October 26, 2022: At today's federal press conference on the upcoming cannabis legalization, the final draft of the key points paper (“Eckpunktepapier”) of the federal government was presented. Among other points, concrete plans relating to the cu...
SynBiotic SE
About the publication
01 September 2022 06:09PM
SynBiotic SE launches full-line medical cannabis brand
DE000A3E5A59
Hempamed Rx: SynBiotic SE launches full-line medical cannabis brand   Europe's largest listed corporate group in the hemp and cannabis sector supports launch with massive expansion of field sales force in the medical cannabis sector   Just in time for Expopharm: SynBiotic SE launches full-range Hempamed Rx brand (Hall B1 / Booth C58) Wide rang...
SynBiotic SE
About the publication
01 September 2022 06:09PM
Hempamed Rx: SynBiotic SE launches full-line medical cannabis brand
DE000A3E5A59
Hempamed Rx: SynBiotic SE launches full-line medical cannabis brand   Europe's largest listed corporate group in the hemp and cannabis sector supports launch with massive expansion of field sales force in the medical cannabis sector   Just in time for Expopharm: SynBiotic SE launches full-range Hempamed Rx brand (Hall B1 / Booth C58) Wide rang...
SynBiotic SE
About the publication
03 August 2022 11:35AM
Becoming a cannabis ecosystem: SynBiotic SE management update
DE000A3E5A59
  Becoming a cannabis ecosystem: SynBiotic SE management update   SynBiotic SE, Europe's largest listed corporate group in the hemp and cannabis sector, on the road to becoming a cannabis ecosystem New products from the corporate group Next annual shareholders’ meeting to be held with live attendance in Q4 2022 SynBiotic group delivers pro-f...
SynBiotic SE
About the publication
03 August 2022 11:35AM
SynBiotic SE management update
DE000A3E5A59
  Becoming a cannabis ecosystem: SynBiotic SE management update   SynBiotic SE, Europe's largest listed corporate group in the hemp and cannabis sector, on the road to becoming a cannabis ecosystem New products from the corporate group Next annual shareholders’ meeting to be held with live attendance in Q4 2022 SynBiotic group delivers pro-f...
SynBiotic SE
About the publication
20 April 2022 08:07PM
Joint venture to launch first cannabis store in Germany
DE000A3E5A59
DGAP-Media / 20.04.2022 / 20:07  SynBiotic SE and Enchilada Group: Joint venture to launch first cannabis store in Germany ●       German cannabis company group SynBiotic SE and franchise expert Enchilada Group to establish joint venture ●       Two new companies to lay foundation for cannabis store franchise ●       Goal: To open Germany's...
SynBiotic SE
About the publication
20 December 2021 10:15PM
SynBiotic SE and key.force: Joint Venture for Germany's largest cannabis sales team
DE000A3E5A59
SynBiotic SE and key.force: Joint Venture for Germany's largest cannabis sales team - SynBiotic SE and key.force start joint venture - With canna.sales GmbH, the leading platform for market access, sales & marketing of products and supply services in the field of medical cannabis is established - Target 2022: Germany's largest cannabis sales...
SynBiotic SE
About the publication
01 December 2021 02:54PM
SynBiotic SE: Most important cannabis merger in Europe
DE000A3E5A59
SynBiotic SE: Most important cannabis merger in Europe - SynBiotic SE acquires 50.1% of Daniel Kruse's group of companies at a valuation of EUR 11.2 million - Hanf Farm GmbH, Hempro International GmbH, Hemp Factory GmbH and MH medical hemp GmbH join the German cannabis group - EIHA President Daniel Kruse and industry pioneer Rafael Dulon bring a...
SynBiotic SE
About the publication
30 November 2021 08:38PM
SynBiotic SE: Majority takeover of hemp industry pioneer Daniel Kruse's group of companies as part of a capital increase in kind
DE000A3E5A59
Insider information pursuant to Article 17 MAR (Ad hoc announcement) NOT FOR PUBLICATION OR DISTRIBUTION, WHETHER DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN, OR WITHIN OR TO ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED. FURTHER RESTRICTIONS APPLY. SynBiotic...
SynBiotic SE
About the publication
27 October 2021 07:56AM
Another seven million Euros for SynBiotic SE
DE000A3E5A59
Munich, October 27, 2021. The cannabis company SynBiotic SE has successfully completed another capital increase. 334,000 new shares were placed with institutional investors at an issue price of EUR 21 per share. With the proceeds of around 7 million Euros, the listed company intends to finance further growth and expansion. A large part of the pro...
SynBiotic SE
About the publication
12 October 2021 10:00AM
SynBiotic SE plans Canadian cross-listing
DE000A3E5A59
DGAP-Media / 12.10.2021 / 10:00 SynBiotic SE plans Canadian cross-listingMunich, October 12, 2021. The cannabis company SynBiotic SE (ISIN: DE000A2LQ777 / WKN: A2LQ77), already listed on the Frankfurt and Düsseldorf stock exchanges, is now to be listed on the Canadian NEO Exchange in Toronto - a new FinTech stock exchange that has been revol...
SynBiotic SE
About the publication
16 September 2021 10:11AM
Christian Angermayer now largest shareholder with circa 45%
DE000A3E5A59
DGAP-Media / 16.09.2021 / 10:11 Apeiron Investment Group acquires all SynBiotic SE shares of Social Chain AG Apeiron Investment Group has acquired all of Social Chain AG's shares in SynBiotic SE. Christian Angermayer's family office has thus significantly increased its shares and is with circa 45 percent now the largest shareholder in Europe...
SynBiotic SE
About the publication
More SYNBIOTIC SE related information
Type Total Last Made by Go to
Corporate Research 3 17th September 2024 EQS Group AG Corporate Research
Directors Dealings 356 13th November 2024 Otto, Frank DD
Short Seller (DE) 0 - - SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN